Effect of Menaquinone supplementation on insulin resistance, lipid profile, anthropometric measurments, endocrine markers and oxidative stress in patients with polycystic ovary syndrome who will be referred to health centers of Shiraz University of Medical Sciences, 1396.

Vice chancellor for research, Shiraz University of Medical Sciences0 个研究点目标入组 84 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•Suffering from polycystic ovary syndrome based on Rotterdam criteria; age between 18 to 40 ; absecnce of pregnancy or lactation; absence of antidiabetic, antihypertensive, antihyperlipidemic, anticoagulant treatment; absence of using metformin 2 months before entering the study and during the intervention; acute or chronic inflammation; absence of any current diet or supplement treatment; absence of antidiabetic, antihypertensive, antihyperlipidemic treatment; absence of using drugs effective on bone metabolism; any disease or physiological changes that requires special treatment; nonsmoker, nonalcoholic. Exclusion criteria: Unwillingness to continue; any disease or physiological changes that requires special treatment; failure to follow the intervention designing (not consuming dedicated supplement to the total amount less than 90% predicted or more than 3 days).

发起方

Vice chancellor for research, Shiraz University of Medical Sciences